Journal of the Korea Academia-Industrial cooperation Society (한국산학기술학회논문지)

The Korea Academia-Industrial cooperation Society (한국산학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Development of an aequorin-based assay for the screening of corticotropin-releasing factor receptor antagonists

CRF1 길항제 스크리닝을 위한 에쿼린 기반 세포실험 개발연구

  • Noh, Hyojin (Department of Biomedical Technology, Sangmyung University) ;
  • Lee, Sunghou (Department of Biomedical Technology, Sangmyung University)
  • 노효진 (상명대학교 의생명공학과) ;
  • 이승호 (상명대학교 의생명공학과)
  • Received : 2015.09.25
  • Accepted : 2015.11.06
  • Published : 2015.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Corticotropin-releasing factor(CRF), one of the stress driven neuropeptides, was widely proposed to influence hair loss and re-growth. For the development of receptor antagonists, the screening system based on intracellular calcium signal process was developed and optimized. The aequorin parental cells were transfected with CRF1 receptor and alpha 16 promiscuous G protein cDNA to establish HEK293a16/hCRF1, a stable cell line for the human CRF1 receptor. In HEK293a16/hCRF1 cells, the range of sauvagine dose response was 12-fold higher($EC_{50}:15.21{\pm}1.83nM$) than in the transiently expressed cells, hence essential conditions for the antagonist screening experiments such as the robust signals and high solvent tolerance were secured. The standard antagonists for the CRF1 receptor, antalarmin and CP154526, resulted $IC_{50}$ values of $414.1{\pm}5.5$ and $290.7{\pm}1.9nM$, respectively. Similar results were presented with frozen HEK293a16/hCRF1 cells. Finally, our HEK293a16/hCRF1 cells with the aequorin based cellular functional assay can be a model system for the development of functional cosmetics and modulators that can have a clinical efficacy on hair re-growth.

corticotropin releasing factor(CRF)는 스트레스에 의해 유도되는 신경펩타이드 물질들 중 하나로서 모발의 손실 및 재성장에 영향을 미친다고 광범위하게 제기되어 왔다. 이에 CRF1 수용체 길항제 개발을 위하여 세포 내 칼슘 신호전달 기전을 이용한 스크리닝 시스템을 개발하고 최적화 연구를 수행하고자 하였다. 이를 위하여 에쿼린 모체세포에 CRF1 수용체와 만능 G 단백질인 G${\alpha}$16 유전자를 동시에 발현시켜 안정화 세포주를 구축하였다(HEK293a16/hCRF1). 표준 효현제인 sauvagine의 반응이 임시 발현세포와 비교하여 안정화 세포주에서 농도 의존적 반응 범위가 12배 이상 증가하였으며($EC_{50}:15.21{\pm}1.83nM$), 이에 따라 길항제 스크리닝에 필수적인 안정적인 신호와 높은 용매 허용도를 확보할 수 있었다. CRF1 수용체에 대한 표준 길항제인 antalarmin과 CP154526에 대한 $IC_{50}$ 수치는 각각 $414.1{\pm}5.5$와 $290.7{\pm}1.9nM$로 확인되었는데 냉동보관세포의 경우에도 유사한 결과를 얻었다. 에쿼린 기반 세포 기능실험의 최적화 연구를 통해 구축된 CRF 수용체 안정화 세포주는 모발의 재형성과 관련된 신규의 기능성 화장품 및 조절물질 개발 연구에 적극적으로 활용 가능 할 것으로 판단된다.

Keywords

References

  1. Lucas, M., Chen, A., Richter-Levin, G. "Hypothalamic corticotropin-releasing factor is centrally involved in learning under moderate stress.", Neuropsychopharmacology, 38(9), 1825-1832, 2013. DOI: http://dx.doi.org/10.1038/npp.2013.82
  2. Arborelius, L., Owens, M.J., Plotsky, P.M., Nemeroff, C. B. "The role of corticotropin-releasing factor in depression and anxiety disorders.", J Endocrinol, 160(1), 1-12, 1999. DOI: http://dx.doi.org/10.1677/joe.0.1600001
  3. Dong, H., Murphy, K.M., Meng, L., Montalvo-Ortiz, J., Zeng, Z., Kolber, B.J., Zhang, S., Muglia, L.J., Csernansky, J.G. "Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.", J Alzheimers Dis, 28(3), 579-592, 2012. https://doi.org/10.3233/JAD-2011-111328
  4. Hillhouse, E.W., Randeva, H., Ladds, G., Grammatopoulos, D. "Corticotropin-releasing hormone receptors.", Biochem Soc Trans, 30(4), 428-432, 2002. DOI: http://dx.doi.org/10.1042/bst0300428
  5. Muramatsu, Y., Suqino, N., Suzuki, T., Totsune, K., Takahashi, K., Tashiro, A., Hongo, M., Oki, Y., Sasano, H. "Urocortin and corticotropin-releasing factor receptor expression in normal cycling human ovaries.", J Clin Endocrinol Metab, 86(3), 1362-1369, 2001. DOI: http://dx.doi.org/10.1210/jcem.86.3.7299
  6. Hemley, C.F., McCluskey, A., Keller, P.A. "Corticotropin releasing hormone-a GPCR drug target.", Curr Drug Targets, 8(1), 105-115, 2007. DOI: http://dx.doi.org/10.2174/138945007779315542
  7. Dautzenberg, F.M., Kilpatrick, G.J., Hauger, R. L., Moreau, J. "Molecular biology of the CRH receptors in the mood.", Peptides, 22(5), 753-760, 2001. DOI: http://dx.doi.org/10.1016/S0196-9781(01)00388-6
  8. Karteris, E., Grammatopoulos, D., Randeva, H., Hillhouse, E.W. "Signal transduction characteristics of the corticotropin-releasing hormone receptors in the feto-placental unit." J Clin Endocrinol Metab, 85, 1989 -1996, 2000. DOI: http://dx.doi.org/10.1210/jcem.85.5.6590
  9. Grammatopoulos, D.K., Randeva, H.S., Levine, M. A., Katsanou, E.S., Hillhouse, E.W. "Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1a and R2b CRH receptor subtypes and stimulation of Gq-proteins.", Mol Endocrinol, 14, 2076 -2091, 2000. DOI: http://dx.doi.org/10.1210/mend.14.12.0574
  10. Kasahara, M., Groenink, L., Olivier, B., Sarnyai, Z. "Corticotropin-releasing factor (CRF) over-expression down-regulates hippocampal dopamine receptor protein expression and CREB activation in mice.", Neuro Endocrinol Lett, 32(2), 193-198, 2011.
  11. Budziszewska, B., Zajac, A., Basta-Kaim, A., Leskiewicz, M., Steczkowska, M., Lason, W., Kacinski, M. "Effects of neurosteroids on the human corticotropin-releasing hormone gene.", Pharmacol Rep, 62(6), 1030-1040, 2010. DOI: http://dx.doi.org/10.1016/S1734-1140(10)70365-0
  12. Wang, L., Million, M., Rivier, J., Rivier, C., Craft, N, Stenzel-Poore, M.P., Tache, Y. "CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice.", PLoS One, 6(2), e16377, 2011. DOI: http://dx.doi.org/10.1371/journal.pone.0016377
  13. Fang, Y. "Ligand-receptor interaction platforms and their applications for drug discovery", Expert Opin Drug Discov, 7, 969-988, 2012. DOI: http://dx.doi.org/10.1517/17460441.2012.715631
  14. Lee, S., "Platform technologies for research on the G protein coupled receptor: Applications to drug discovery research", Biomol Therapeutics, 19, 1-8, 2011. DOI: http://dx.doi.org/10.4062/biomolther.2011.19.1.001
  15. Peters, M.F., Vaillancourt, F., Heroux, M., Valiquette, M. and Scott, C.W. "Comparing label-free biosensors for pharmacological screening with cell-based functional assays", Assay & Drug Develop Tech, 8, 219-227, 2010. DOI: http://dx.doi.org/10.1089/adt.2009.0232
  16. Button, D., Brownstein, M. "Aequorin- expressing mammalian cell line used to report Ca2+ mobilization.", Cell Calcium, 14(9):663-671, 1993. DOI: http://dx.doi.org/10.1016/0143-4160(93)90091-J
  17. Eglen, R.M. and Reisine, T. "Photoproteins: Important new tools in drug discovery", Assay & Drug Develop Tech, 6, 659-671, 2008. DOI: http://dx.doi.org/10.1089/adt.2008.160
  18. Inouye, S., Noguchi, M., Sakaki, Y., Takagi, Y., Miyata, T., Iwanaga, S. and Tsuji, F.I. "Cloning and sequence analysis of cdna for the luminescent protein aequorin", Proc Natl Acad Sci U S A, 82, 3154-3158, 1985. DOI: http://dx.doi.org/10.1073/pnas.82.10.3154
  19. Prasher, D., McCann, R.O. and Cormier, M.J. "Cloning and expression of the cdna coding for aequorin, a bioluminescent calcium-binding protein", Biochem Biophys Res Commun, 126, 1259-1268, 1985. DOI: http://dx.doi.org/10.1016/0006-291X(85)90321-3
  20. Dupriez, V.J., Maes, K., Le Poul, E., Burgeon, E. and Detheux, M. "Aequorin-based functional assays for g-protein-coupled receptors, ion channels, and tyrosine kinase receptors", Receptors Channels, 8, 319-330, 2002. DOI: http://dx.doi.org/10.1080/10606820214646
  21. Ueda, T., Ugawa, S., Ishida, Y., Hondoh, A. and Shimada, S. "Development of generic calcium imaging assay for monitoring gi-coupled receptors and g-protein interaction", J Biomol Screen, 14, 781-788, 2009. DOI: http://dx.doi.org/10.1177/1087057109335258
  22. Noh, H., Lee, S. "Optimization of the cryopreserved condition for utilization of GPCR frozen cells", J Korea Acad Cooper Soc, 16(2), 1200-1206, 2015. DOI: http://dx.doi.org/10.5762/kais.2015.16.2.1200
  23. Dautzenberg, F.M., Gutknecht, E., Van der Linden, I., Olivares-Reyes, J.A., Durrenberger, F. and Hauger, R.L. "Cell-type specific calcium signaling by corticotropinreleasing factor type 1 (crf1) and 2a (crf2(a)) receptors: Phospholipase c-mediated responses in human embryonic kidney 293 but not sk-n-mc neuroblastoma cells", Biochem Pharmacol, 68, 1833-1844, 2004. DOI: http://dx.doi.org/10.1016/j.bcp.2004.07.013
  24. Huang, H.J. and Chen, C.Y. "A possible solution for hair loss by inhibiting corticotropin-releasing factor (crf) receptor from traditional chinese medicine", J Biomol Str & Dynamics, 32, 1613-1623, 2014. DOI: http://dx.doi.org/10.1080/07391102.2013.831377
  25. Zhang, J.H., Chung, T.D., Oldenburg, K.R. "A simple statistical parameter for use in evaluation and validation of high throughput screening assays", J Biomol Screen, 4, 67-73, 1999. DOI: http://dx.doi.org/10.1177/108705719900400206